法罗培南治疗急性细菌感染性疾病临床对照研究  

A clinical control study of faropenem in treatment of acute bacterial infections

作　　者：李建华[1] 张力燕[1] 王华[1] 宋丰贵[1] 徐加相 杨绍明 胡福定[4] 

机构地区：[1]昆明医学院第一附属医院呼吸内科,云南昆明650032 [2]云南省红十字会医院急诊科,云南昆明650200 [3]昆明市五华区人民医院内科,云南昆明650031 [4]云南省第一人民医院呼吸内科,云南昆明650032

出　　处：《中国新药与临床杂志》2009年第5期355-359,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的评价法罗培南治疗的呼吸、泌尿系统细菌感染性疾病的疗效和安全性。方法采用多中心随机单盲阳性药平行对照试验方法。共入选有效病例226例,试验组114例,对照组112例。试验组予法罗培南口服,每次200mg,每日3次;对照组予头孢泊肟口服,每次100mg,每日2次,疗程均为7～14d。比较2组临床疗效及不良反应。结果试验组与对照组临床痊愈率分别为83.3%和80.4%,有效率分别为95.6%和95.5%,2组临床疗效比较无显著差异(P>0.05)。细菌清除率均为99%,组间无显著差异(P>0.05)。药物不良反应发生率分别为6.8%和6.1%,组间差异无显著意义(P>0.05)。结论法罗培南治疗临床常见急性细菌感染性疾病安全、有效。AIM To evaluate the efficacy and safety of faropenem in the treatment of respiratory and urinary bacterial infections. METHODS A single blind randomized, parallel controlled, muhicenter clinical trial was carried out. In the study, 114 patients were enrolled in trial group （faropenem 200 mg, 3 times daily）and another 112 patients enrolled in control group （cefpodoxime 100 mg, 2 times daily）, with a course of 7 to 14 days for both groups. The clinical efficacy and safety together with adverse reactions were investigated and compared. RESULTS The cure rates and total effective rates for the trial and control groups were 83.3%, 80.4% 95.6%, and 95.5%, respectively. The bacterial clearance rates were both 99%, and the incidences of drug adverse reaction were 6.8% and 6.1%, respectively. There were no statistically significant differences between the results of both groups （P 〉 0.05） . CONCLUSION Faropenem is effective and safe for treating acute bacterial infection.

关 键 词：细菌感染 随机对照试验 多中心研究 法罗培南 

分 类 号：R978.1[医药卫生—药品]